MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease

Background: Clinical trials have shown that subcutaneous (sc) pasireotide effectively decreases urinary free cortisol (UFC), improves signs/symptoms and has a favorable safety profile in patients with Cushing’s disease (CD). We describe interim long-term safety and efficacy results of an ongoing mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuen, Kevin, Giordano, Carla, Deutschbein, Timo, Manetti, Luca, Roughton, Michael, Kriemler-Krahn, Ulrike, Tauchmanova, Libuse, Maamari, Ricardo, Schopohl, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551095/
http://dx.doi.org/10.1210/js.2019-MON-445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551095/
http://dx.doi.org/10.1210/js.2019-MON-445

Ejemplares similares